We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare to Acquire Intelerad for $2.3B to Boost Cloud Imaging
Read MoreHide Full Article
Key Takeaways
GEHC is likely to acquire Intelerad for $2.3B to expand its cloud-enabled imaging capabilities.
The deal brings strong outpatient and ambulatory reach to enhance GEHC's imaging ecosystem.
Intelerad adds 90% recurring revenue and expected low double-digit growth as GEHC targets a 2026 close.
GE HealthCare (GEHC - Free Report) recently announced an agreement to acquire Intelerad, a leading cloud-based medical imaging software provider, in a $2.3 billion all-cash deal. The acquisition aligns with GEHC’s strategy to expand its cloud-enabled and AI-powered capabilities across both inpatient and rapidly growing outpatient care settings, supporting the company’s long-term precision care vision.
The deal is likely to bring in Intelerad’s strong outpatient and ambulatory presence into GEHC’s already established hospital-based imaging portfolio, creating a more connected enterprise imaging ecosystem. Management expects the combination to accelerate SaaS growth, increase recurring revenue and strengthen GEHC’s competitive positioning as demand for scalable cloud imaging solutions continues to rise globally.
Likely Trend of GEHC Stock Following the News
Following the announcement, the company's shares traded flat at Friday’s closing. In the year-to-date period, shares have lost 2.3% against the industry’s 3.4% growth. The S&P 500 has gained 13.7% in the same time frame.
In the long run, the acquisition is expected to enhance GEHC’s growth profile by expanding into the fast-growing outpatient imaging segment and accelerating its shift toward a high-margin, recurring SaaS revenue model. By combining GEHC’s clinical imaging and AI strengths with Intelerad’s cloud-first platform and workflow management capabilities, the company is positioned to deliver more integrated solutions, improve customer retention, and unlock meaningful cost and revenue synergies. This should support stronger margins and more predictable long-term performance.
GEHC currently has a market capitalization of $34.8 billion.
Image Source: Zacks Investment Research
More on the Acquisition News
GEHC has agreed to acquire Intelerad for a purchase price of $2.3 billion in cash, marking a significant expansion into cloud-based enterprise imaging. Intelerad is a major provider of medical imaging and workflow management software with a strong presence in outpatient and ambulatory care settings, complementing GEHC’s hospital-focused footprint. The transaction includes plans to integrate Intelerad’s radiology and cardiology cloud platforms, cloud PACS, AI-enabled workflow tools, and image sharing solutions into GEHC’s product portfolio.
The deal is expected to close in the first half of 2026, subject to regulatory approvals and standard closing conditions. GEHC intends to finance the acquisition through cash on hand and debt financing. Intelerad is projected to generate approximately $270 million in revenues in the first full year, with around 90% recurring revenue and an adjusted EBITDA margin of more than 30%. Revenue currently grows in the low double digits and is expected to accelerate post-integration. The transaction is expected to be immediately accretive to GEHC’s top-line growth and adjusted EBIT margin, slightly dilutive to adjusted EPS in the short term, and targeting a high-single-digit return on invested capital by year five.
Benefits of the Acquisition to GEHC
This acquisition strengthens GE HealthCare’s long-term strategic positioning by expanding its reach into the rapidly growing outpatient and ambulatory imaging market, a segment valued at more than $2 billion globally and expected to grow at a double-digit pace. With healthcare providers increasingly shifting imaging procedures outside hospitals and seeking unified, scalable platforms, GEHC gains an opportunity to serve a broader customer base across multiple care settings. The deal also supports the company’s push to triple its cloud-enabled product offerings by 2028, aligning with ongoing demand for integrated digital solutions that improve operational efficiency and clinical productivity.
Financially, the addition of Intelerad’s recurring SaaS revenue model strengthens GEHC’s earnings quality and predictability, helping drive a more durable growth profile. The acquisition is expected to boost revenue growth and expand margins immediately upon closing, supported by meaningful cost efficiencies and cross-selling opportunities across GEHC’s global footprint. Over time, the integration is anticipated to deliver stronger profitability and improved return on capital, reinforcing GEHC’s transition toward a solutions-driven, higher-margin digital healthcare business.
GEHC’s Zacks Rank & Key Picks
Currently, GEHC carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , Intuitive Surgical (ISRG - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 14.28%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a third-quarter 2025 adjusted EPS of $2.40, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion outperformed the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GE HealthCare to Acquire Intelerad for $2.3B to Boost Cloud Imaging
Key Takeaways
GE HealthCare (GEHC - Free Report) recently announced an agreement to acquire Intelerad, a leading cloud-based medical imaging software provider, in a $2.3 billion all-cash deal. The acquisition aligns with GEHC’s strategy to expand its cloud-enabled and AI-powered capabilities across both inpatient and rapidly growing outpatient care settings, supporting the company’s long-term precision care vision.
The deal is likely to bring in Intelerad’s strong outpatient and ambulatory presence into GEHC’s already established hospital-based imaging portfolio, creating a more connected enterprise imaging ecosystem. Management expects the combination to accelerate SaaS growth, increase recurring revenue and strengthen GEHC’s competitive positioning as demand for scalable cloud imaging solutions continues to rise globally.
Likely Trend of GEHC Stock Following the News
Following the announcement, the company's shares traded flat at Friday’s closing. In the year-to-date period, shares have lost 2.3% against the industry’s 3.4% growth. The S&P 500 has gained 13.7% in the same time frame.
In the long run, the acquisition is expected to enhance GEHC’s growth profile by expanding into the fast-growing outpatient imaging segment and accelerating its shift toward a high-margin, recurring SaaS revenue model. By combining GEHC’s clinical imaging and AI strengths with Intelerad’s cloud-first platform and workflow management capabilities, the company is positioned to deliver more integrated solutions, improve customer retention, and unlock meaningful cost and revenue synergies. This should support stronger margins and more predictable long-term performance.
GEHC currently has a market capitalization of $34.8 billion.
Image Source: Zacks Investment Research
More on the Acquisition News
GEHC has agreed to acquire Intelerad for a purchase price of $2.3 billion in cash, marking a significant expansion into cloud-based enterprise imaging. Intelerad is a major provider of medical imaging and workflow management software with a strong presence in outpatient and ambulatory care settings, complementing GEHC’s hospital-focused footprint. The transaction includes plans to integrate Intelerad’s radiology and cardiology cloud platforms, cloud PACS, AI-enabled workflow tools, and image sharing solutions into GEHC’s product portfolio.
The deal is expected to close in the first half of 2026, subject to regulatory approvals and standard closing conditions. GEHC intends to finance the acquisition through cash on hand and debt financing. Intelerad is projected to generate approximately $270 million in revenues in the first full year, with around 90% recurring revenue and an adjusted EBITDA margin of more than 30%. Revenue currently grows in the low double digits and is expected to accelerate post-integration. The transaction is expected to be immediately accretive to GEHC’s top-line growth and adjusted EBIT margin, slightly dilutive to adjusted EPS in the short term, and targeting a high-single-digit return on invested capital by year five.
Benefits of the Acquisition to GEHC
This acquisition strengthens GE HealthCare’s long-term strategic positioning by expanding its reach into the rapidly growing outpatient and ambulatory imaging market, a segment valued at more than $2 billion globally and expected to grow at a double-digit pace. With healthcare providers increasingly shifting imaging procedures outside hospitals and seeking unified, scalable platforms, GEHC gains an opportunity to serve a broader customer base across multiple care settings. The deal also supports the company’s push to triple its cloud-enabled product offerings by 2028, aligning with ongoing demand for integrated digital solutions that improve operational efficiency and clinical productivity.
Financially, the addition of Intelerad’s recurring SaaS revenue model strengthens GEHC’s earnings quality and predictability, helping drive a more durable growth profile. The acquisition is expected to boost revenue growth and expand margins immediately upon closing, supported by meaningful cost efficiencies and cross-selling opportunities across GEHC’s global footprint. Over time, the integration is anticipated to deliver stronger profitability and improved return on capital, reinforcing GEHC’s transition toward a solutions-driven, higher-margin digital healthcare business.
GEHC’s Zacks Rank & Key Picks
Currently, GEHC carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , Intuitive Surgical (ISRG - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 14.28%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a third-quarter 2025 adjusted EPS of $2.40, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion outperformed the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.